Enovis (NYSE:ENOV) Stock: Insider Sharon Wienbar Buys 924 Shares

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar bought 924 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were bought at an average cost of $26.98 per share, for a total transaction of $24,929.52. Following the purchase, the director owned 43,777 shares of the company’s stock, valued at approximately $1,181,103.46. The trade was a 2.16% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Enovis Stock Up 1.4%

Shares of ENOV opened at $28.62 on Thursday. Enovis Corporation has a 52 week low of $16.70 and a 52 week high of $32.41. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -3.11 and a beta of 1.31. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. The stock has a fifty day moving average of $20.21 and a 200-day moving average of $23.16.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $558.73 million for the quarter, compared to the consensus estimate of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. Enovis’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. As a group, sell-side analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enovis

A number of hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc lifted its stake in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after acquiring an additional 1,174 shares during the period. Allworth Financial LP acquired a new stake in Enovis during the 2nd quarter valued at approximately $36,000. Integrated Wealth Concepts LLC acquired a new stake in Enovis during the 2nd quarter valued at approximately $39,000. Public Employees Retirement System of Ohio acquired a new stake in Enovis during the 2nd quarter valued at approximately $48,000. Finally, SBI Securities Co. Ltd. bought a new position in Enovis during the 3rd quarter worth approximately $55,000. 98.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ENOV shares. Canaccord Genuity Group reduced their target price on shares of Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a report on Friday, November 6th. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wells Fargo & Company lifted their price target on shares of Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Finally, Needham & Company LLC boosted their price objective on shares of Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.62.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.